NVG-2089

DRUG4 trials

Sponsors

Nuvig Therapeutics Inc., Nuvig Therapeutics, Inc.

Conditions

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immune Thrombocytopenia (ITP)

Phase 2

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

RecruitingCTIS2024-515386-34-00

Nuvig Therapeutics Inc.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: 2025-05-29Target: 99Updated: 2025-07-22

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

RecruitingNCT07027111

Nuvig Therapeutics, Inc.Chronic Inflammatory Demyelinating Polyneuropathy

Start: 2025-04-25End: 2028-06-30Target: 60Updated: 2025-06-18

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

RecruitingNCT07095127

Nuvig Therapeutics, Inc.Immune Thrombocytopenia (ITP)

Start: 2025-09-30End: 2026-12-31Target: 10Updated: 2025-07-31

An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia

RecruitingCTIS2024-520359-26-00

Nuvig Therapeutics Inc.Immune Thrombocytopenia (ITP)

Start: 2025-08-20Target: 25Updated: 2025-09-04